Company news

Awakn Life Sciences Corp news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CSE Bulletin: Delist - Awakn Life Sciences Corp. (AWKN)

May 27, 2025

Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc

May 27, 2025

Awakn Life Sciences Announces Shareholder Approval of Arrangement

April 23, 2025

Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement

April 11, 2025

Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc

February 27, 2025

Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD

January 27, 2025

Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder

January 20, 2025

Awakn Life Sciences Announces Credit Facility

December 18, 2024

Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

December 16, 2024

Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

December 10, 2024

Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites

October 22, 2024

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

October 15, 2024

Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

October 4, 2024

Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

September 18, 2024

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

August 28, 2024

Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder

August 9, 2024

Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

July 31, 2024

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

July 22, 2024

Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

July 18, 2024

Awakn Life Sciences Announces Closing of Tranche of Private Placement

June 4, 2024

CSE Bulletin: Reinstatement - Awakn Life Sciences Corp. (AWKN)

May 31, 2024

CSE Bulletin: Suspensions - AWKN, BHCC, BZAM, GLOW, VTAL, JKPT, MEAL,VFI.X, STHZ

May 8, 2024

Awakn Life Sciences Discusses Filing of Financial Statements

May 2, 2024

Awakn Life Sciences Announces Closing of Tranche of Private Placement

April 17, 2024

Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic

April 3, 2024

CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)

February 12, 2024

Awakn Life Sciences Announces Listing on the Canadian Securities Exchange

February 12, 2024